for the ketamine Abbreviated New Drug Application, which was assigned a Generic Drug User Fee Amendments of 2022 (“GDUFA”) goal date of October 29, 2024. On November 12, 2024, the FDA granted the ...

DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...

Advances in clinical development keep the hope alive of having new drugs in the not-so-distant future to complement the ... a ...

When he was a federal appeals court judge, the future Trump appointee wrote critically of the federal Analogue Act. The ...

The global artificial intelligence (AI) in drug discovery market is projected to reach USD 6.89 billion by 2029 from USD 1.86 ...

Altimmune ( (ALT) ) has released its Q3 earnings. Here is a breakdown of the information Altimmune presented to its investors. Altimmune, Inc.

While A.I. promises breakthroughs, industry leaders warn that transparency and patient safety must remain front and center.

In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...

"LAI formulations are becoming increasingly important in pharmaceutical pipelines and product portfolios due to their ability to improve patient compliance and deliver extended drug release," said Dr.

The Nasal Drug Delivery Technology Market is driven by the rising demand for non-invasive administration methods that enhance patient compliance and bioavailability. Innovations such as advanced ...